A randomized double-blind, double dummy, placebo-controlled, parallel-group, multicenter dose ranging study to evaluate the efficacy and safety of GW685698X inhalation powder once daily and fluticasone propionate inhalation powder twice daily compared with placebo for 8 weeks in adolescent and adult subjects with persistent asthma symptomatic on low-dose ICS therapy.

Trial Profile

A randomized double-blind, double dummy, placebo-controlled, parallel-group, multicenter dose ranging study to evaluate the efficacy and safety of GW685698X inhalation powder once daily and fluticasone propionate inhalation powder twice daily compared with placebo for 8 weeks in adolescent and adult subjects with persistent asthma symptomatic on low-dose ICS therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs Fluticasone furoate (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.
    • 22 Sep 2010 Results presented at the European Respiratory Society congress, accoding to a GSK media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top